All-new research in dermatology is available now – take a look at this month’s new and exclusive content on JDDonline.com:
- In a multicenter clinical study, investigators conduct an analysis of data on the Effect of Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam on Target Lesions in Plaque Psoriasis: A Post-Hoc Analysis
-
Authors evaluate Intralesional Triamcinolone Acetonide in the Treatment of Traction Alopecia in a retrospective chart review of TA patients treated with ILK at an academic dermatology clinic.
-
Real-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab highlights the safety and efficacy and unique mechanisms of action of the IL-17 inhibitors.
-
Real-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab highlights the safety and efficacy and unique mechanisms of action of the IL-17 inhibitors.
- The IL-17 pathway plays a crucial role in the immunopathogenesis and development of psoriasis in Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis.
-
A Survey of Dermatologists’ Preparedness for Natural and Manmade Disasters examines whether the dermatology field has advanced in its bioterrorism preparedness since a 2003 survey revealed 88% of dermatologists felt unprepared to respond to a biological attack.
View all February JDD content, including editor’s picks, supplements, CME activities, case reports, and more!
Read Now
You May Also Like
La Roche-Posay: Intercepting Melanin Precursors for Next-Generation Dark Spot Correction
La Roche-Posay: Intercepting Melanin Precursors for Next-Generation Dark Spot Correction
Join Janiene Luke, MD, to discover how MELAB3’s breakthrough active, Melasyl (2 MNG), intercepts melanin precursors before they form dark spots, setting a new standard for safety and efficacy across…
New Video Abstract: Efficacy of a Dual-Serum Cosmetic System in Women With Female Pattern Hair Loss
New Video Abstract: Efficacy of a Dual-Serum Cosmetic System in Women With Female Pattern Hair Loss
Hair loss is a widespread condition with a potentially severe psychological burden, especially among women. The chance of suffering from female alopecia increases with menopause, and topical treatments beyond minoxidil…
JDD in the News: Ruxolitinib vs. Triamcinolone for Atopic Dermatitis
JDD in the News: Ruxolitinib vs. Triamcinolone for Atopic Dermatitis
MedPage Today/Dermatology World Weekly highlighted a Journal of Drugs in Dermatology study comparing a topical JAK inhibitor with a common topical steroid in atopic dermatitis (AD). The study, “Ruxolitinib Cream…
